Promega Corporation, Fitchburg, Wisconsin 53711.
Promega Biosciences LLC, San Luis Obispo, California 93401.
J Biol Chem. 2020 Apr 10;295(15):5124-5135. doi: 10.1074/jbc.RA119.011952. Epub 2020 Feb 27.
G protein-coupled receptors (GPCRs) are prominent targets to new therapeutics for a range of diseases. Comprehensive assessments of their cellular interactions with bioactive compounds, particularly in a kinetic format, are imperative to the development of drugs with improved efficacy. Hence, we developed complementary cellular assays that enable equilibrium and real-time analyses of GPCR ligand engagement and consequent activation, measured as receptor internalization. These assays utilize GPCRs genetically fused to an N-terminal HiBiT peptide (1.3 kDa), which produces bright luminescence upon high-affinity complementation with LgBiT, an 18-kDa subunit derived from NanoLuc. The cell impermeability of LgBiT limits signal detection to the cell surface and enables measurements of ligand-induced internalization through changes in cell-surface receptor density. In addition, bioluminescent resonance energy transfer is used to quantify dynamic interactions between ligands and their cognate HiBiT-tagged GPCRs through competitive binding with fluorescent tracers. The sensitivity and dynamic range of these assays benefit from the specificity of bioluminescent resonance energy transfer and the high signal intensity of HiBiT/LgBiT without background luminescence from receptors present in intracellular compartments. These features allow analyses of challenging interactions having low selectivity or affinity and enable studies using endogenously tagged receptors. Using the β-adrenergic receptor family as a model, we demonstrate the versatility of these assays by utilizing the same HiBiT construct in analyses of multiple aspects of GPCR pharmacology. We anticipate that this combination of target engagement and proximal functional readout will prove useful to the study of other GPCR families and the development of new therapeutics.
G 蛋白偶联受体 (GPCRs) 是许多疾病新型治疗药物的重要靶标。全面评估它们与生物活性化合物的细胞相互作用,特别是在动力学模式下,对于开发疗效提高的药物至关重要。因此,我们开发了互补的细胞测定法,能够平衡和实时分析 GPCR 配体的结合及其随后的激活,以受体内化来衡量。这些测定法利用与 N 端 HiBiT 肽(1.3 kDa)融合的 GPCR,当与 LgBiT(一种源自 NanoLuc 的 18 kDa 亚基)高度亲和互补时,会产生明亮的荧光。LgBiT 的细胞不可渗透性将信号检测限制在细胞表面,并通过细胞表面受体密度的变化来测量配体诱导的内化。此外,生物发光共振能量转移用于通过与荧光示踪剂竞争结合来量化配体与其同源 HiBiT 标记 GPCR 之间的动态相互作用。这些测定法的灵敏度和动态范围受益于生物发光共振能量转移的特异性和 HiBiT/LgBiT 的高信号强度,而没有细胞内区室中存在的受体的背景荧光。这些特性允许分析具有低选择性或亲和力的具有挑战性的相互作用,并能够使用内源性标记的受体进行研究。我们以β肾上腺素能受体家族为例,通过在 GPCR 药理学的多个方面分析中利用相同的 HiBiT 构建体,展示了这些测定法的多功能性。我们预计这种靶标结合和近端功能读数的组合将有助于研究其他 GPCR 家族和开发新的治疗方法。